Jim Hens Joins Providence Medical Technology as CCO Amidst Growth

Providence Medical Technology Appoints New Chief Commercial Officer

Providence Medical Technology, a trailblazer in the field of spinal fusion surgery technology, has recently announced a significant leadership change. The company has appointed Jim Hens as the new Chief Commercial Officer (CCO), marking a bold step in its mission to advance commercial growth and capitalize on a recent surge in industry interest.

Jim Hens brings with him a wealth of experience, boasting over 25 years of leadership in the orthopedic and spine sectors. His recent tenure as Managing Director for Silony Spine in the U.S. saw him at the helm of all operations, further showcasing his extensive expertise. Before that, Hens served as General Manager at NuVasive, where he drove record growth for one of the company’s largest divisions for three consecutive years.

Hens’ appointment comes at a pivotal time for Providence. The company is experiencing rapid expansion following the publication of its landmark 202-patient FUSE Study in the prominent journal, Spine. This study, a first of its kind, highlights the superior clinical outcomes achieved through multi-level Circumferential Cervical Fusion (CCF) when compared to the traditional Anterior Cervical Discectomy and Fusion (ACDF). The favorable results from this groundbreaking study are expected to elevate demand for Providence's innovative technologies.

Scott Lynch, Chief Product Officer at Providence, expressed enthusiasm about Hens joining the team. He highlighted the current momentum within the company, stating, "Jim is a rare talent who combines deep operational expertise and spine industry knowledge with a visionary approach to sales leadership. His ability to lead high-performance teams will be vital as we work to establish CCF as the standard of care for cervical spine patients and expand adoption of our CORUS technology within lumbar spine fusion cases."

In taking on this new role, Hens stated, "I am thrilled to join Providence. The data from the FUSE study is a watershed moment for the industry, demonstrating that we can significantly reduce surgical failures via a tissue-sparing, circumferential approach. I look forward to collaborating with this outstanding team to ensure that surgeons have all necessary instruments, implants, and support to achieve remarkably higher fusion success rates for their patients."

Strategies for Growth

Looking ahead, Providence is poised for substantial growth in 2025. The company made significant strides in its business strategy last year, including the expansion of its direct sales force and the successful launch of its PCSS product line, alongside introducing lumbar navigational-compatible products to improve CORUS technology for lumbar spinal fusions.

The focus on solid patient outcomes backed by rigorous clinical research and distinct product designs has already spurred an impressive 40% revenue growth for the company during 2024 and 2025. Furthermore, Providence's unique business model has allowed it to achieve two consecutive years of positive Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) while also heavily investing in clinical trials and innovative product development.

About Providence Medical Technology

Providence Medical Technology operates as a privately held medical device company located in Pleasanton, California. The company is dedicated to enhancing clinical outcomes for spinal fusion patients while minimizing the risk of surgical failures through its tissue-sparing, clinically validated solutions, including the notable CORUS™ technology.

As always, potential risks associated with any medical device should be carefully considered and understood. For detailed risk information and contraindications, users are encouraged to consult the device labeling or visit the official Providence Medical Technology website at providencemt.com/safety.

The strides that Providence Medical Technology is making in the spinal surgery domain signify an exciting trajectory as they prepare to set a new standard in surgical outcomes and patient care.